Soleno Therapeutics, Inc.

DB:6XC Stock Report

Market Cap: €2.4b

Soleno Therapeutics Valuation

Is 6XC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6XC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6XC (€53) is trading below our estimate of fair value (€287.46)

Significantly Below Fair Value: 6XC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6XC?

Key metric: As 6XC is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 6XC. This is calculated by dividing 6XC's market cap by their current book value.
What is 6XC's PB Ratio?
PB Ratio9.3x
BookUS$264.70m
Market CapUS$2.49b

Price to Book Ratio vs Peers

How does 6XC's PB Ratio compare to its peers?

The above table shows the PB ratio for 6XC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
BIO3 Biotest
2x29.3%€1.4b
FYB Formycon
1.5x31.5%€848.4m
HPHA Heidelberg Pharma
3x-33.0%€102.1m
2INV 2invest
1xn/a€62.7m
6XC Soleno Therapeutics
9.3x67.3%€2.5b

Price-To-Book vs Peers: 6XC is expensive based on its Price-To-Book Ratio (9.3x) compared to the peer average (1.8x).

Price to Book Ratio vs Industry

How does 6XC's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
6XC 9.3xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 6XC is expensive based on its Price-To-Book Ratio (9.3x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 6XC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6XC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio9.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 6XC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6XC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€53.00
€69.28
+30.7%
10.1%€86.77€62.51n/a8
Nov ’25€50.65
€68.02
+34.3%
12.4%€85.98€56.39n/a7
Oct ’25€43.50
€65.05
+49.5%
13.3%€83.52€54.78n/a7
Sep ’25€41.54
€62.84
+51.3%
15.1%€83.15€52.75n/a7
Aug ’25€44.16
€62.37
+41.2%
17.0%€86.21€54.69n/a7
Jul ’25€37.34
€62.37
+67.0%
17.0%€86.21€54.69n/a7
Jun ’25€38.58
€62.37
+61.7%
17.0%€86.21€54.69n/a7
May ’25€34.78
€60.78
+74.8%
20.2%€86.74€47.57n/a6
Apr ’25€38.70
€59.26
+53.1%
21.2%€85.66€46.98n/a6
Mar ’25€44.00
€58.21
+32.3%
23.7%€85.71€40.55n/a6
Feb ’25€42.10
€49.25
+17.0%
13.3%€57.89€40.43n/a5
Jan ’25n/a
€45.90
0%
13.2%€53.63€39.99n/a4
Dec ’24n/a
€41.70
0%
17.6%€54.07€35.74n/a4
Nov ’24€22.20
€35.07
+58.0%
7.6%€36.97€31.28€50.653
Oct ’24€20.20
€35.64
+76.4%
5.0%€36.90€33.12€43.503
Sep ’24€4.44
€11.24
+153.1%
38.8%€17.31€7.29€41.543
Aug ’24€4.55
€11.21
+146.3%
38.8%€17.27€7.27€44.163
Jul ’24€3.79
€8.20
+116.3%
11.1%€9.11€7.29€37.342
Jun ’24€4.83
€8.20
+69.7%
11.1%€9.11€7.29€38.582
May ’24€2.88
€8.36
+190.4%
11.1%€9.29€7.44€34.782
Apr ’24€1.99
€8.36
+320.3%
11.1%€9.29€7.44€38.702
Mar ’24€1.88
€8.28
+340.6%
11.1%€9.20€7.36€44.002
Feb ’24€2.62
€8.28
+216.1%
11.1%€9.20€7.36€42.102
Jan ’24€1.78
€8.48
+376.2%
11.1%€9.42€7.54n/a2
Dec ’23€1.02
€8.71
+753.7%
11.1%€9.68€7.74n/a2
Nov ’23€0.99
€20.01
+1,911.5%
50.0%€30.02€10.01€22.202

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$16.05

7D

4.9%

1Y

79.5%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.71

7D

0.4%

1Y

-33.2%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$28.60

7D

2.1%

1Y

21.2%